Quiz: Radionuclide Therapy A multiple-choice quiz consists of: 10 QuestionsQuestions are selected randomly from a collection of 17 questions. More Questions You will get deferent questions every time you take the quiz. Correct AnswersThere could be more than one correct answer, select all that apply.Skip QuestionsYou are allowed to scroll backward and forward before submitting your answers.10 MinutesThe quiz has a time limit. Time's up You can still submit your answers after the allowed period of time has ended . When ready, click Next to start the quiz. Name (Required) Email (Optional) Twitter (Optional) 1. Transient increase in tracer uptake in responding metastases in the early months after chemotherapy/hormone therapy for breast and prostate cancer is called: Flare phenomenon. Super phenomenon. Super scan. Flare scan. 2. To reduce radiation exposure to the patient undergoing radioactive iodine (RAI) treatment, all of the following recommendations will be helpful EXCEPT: Patient should urinate frequently Patient should be well hydrated Patient should use antiperspirant medications Patient laxatives 3. An ultimate treatment for patients who are nonresponsive to or cannot tolerate other available therapies for a particular illness and whose prognosis is often poor is called: Retreatment. Standard therapy. Consolidation therapy. Salvage therapy. 4. All breastfeeding women undergoing I-131 therapy should be asked to stop breastfeeding and therapy is delayed until lactation ceases. According to the Society of Nuclear Medicine (SNM) procedure guidelines, the patient may resume breastfeeding: Never. After 3 months. After 6 months. With the birth of another child. 5. Samarium-153 (Quadramet) is a therapeutic radiopharmaceutical used to treat: Medullary thyroid carcinoma Polycythemia vera Dyspnea in lung Ca Pain in bony metastases 6. Treatment of hyperthyroidism with antithyroid medications must be given for 6 months to 2 years, in order to be effective. The two main antithyroid drugs are: Methimazole and Propranolol Methimazole and Propylthiouracil Metronidazole and Propylthiouracil Metronidazole and Propranolol 7. The general pretreatment requirements for adult qualifying for therapy with I-131 metaiodobenzylguanidine (MIBG) include the following EXCEPT: Reviewing potential interfering medications A diagnostic MIBG scan or previous posttreatment I-131 MIBG scan Blocking thyroid uptake of free radioiodine Performing pulmonary function tests 8. According to the Society of Nuclear Medicine “SNM Procedure Guideline for Therapy of Thyroid Disease with I-131 (Sodium Iodide),” typically administered activity for treatment of presumed thyroid cancer in the neck or mediastinal lymph nodes is in the range: 50–100 mCi. 100–150 mCi. 150–200 mCi. 200–250 mCi. 9. What is the predominant toxicity of radioisotopes used in the treatment of bone metastases? Gastritis Leukemia Myelosuppression Radiation pneumonitis 10. The hematologic toxicity of Y-90 Zevalin therapy is common. All of the following can be a sign of hematologic toxicity EXCEPT: Bruising Arrhythmia Anemia Fever 1 out of 10 Time's upTime is Up! By Nasser AlMutairi|2021-09-20T13:15:38+03:00April 26th, 2021|Radionuclide Therapy| Share This Post With Others! FacebookXLinkedInWhatsAppPinterestEmail About the Author: Nasser AlMutairi Senior Nuclear Medicine Specialist at Hafar Al-Batin Central Hospital, Founder of NuclearMed Website. Leave a ReplyCancel reply
Leave a Reply